Roberto Pili

  • 10487 Citations
  • 50 h-Index
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1990 2019

Filter
Article
2019

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Jan 1 2019, In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Maximum Tolerated Dose
Neoplasms
Safety
Vascular Endothelial Growth Factor A

Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA

Gawroński, A. R., Lin, Y. Y., McConeghy, B., LeBihan, S., Asghari, H., Koçkan, C., Orabi, B., Adra, N., Pili, R., Collins, C. C., Sahinalp, S. C. & Hach, F., Apr 23 2019, In : Nucleic acids research. 47, 7, p. e38

Research output: Contribution to journalArticle

Open Access
DNA
Neoplasms
Clone Cells
Workflow
Prostatic Neoplasms

TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)

Bunch, B., Krishnan, N., Greenspan, R. D., Ramakrishnan, S., Attwood, K., Yan, L., Qi, Q., Wang, D., Morrison, C., Omilian, A., Bshara, W., Pili, R., Trump, D. L., Johnson, C. & Woloszynska, A., Sep 2 2019, In : Cell Cycle. 18, 17, p. 2055-2066 12 p.

Research output: Contribution to journalArticle

Urinary Bladder Neoplasms
Methylation
Cisplatin
decitabine
Muscles
2018
17 Citations (Scopus)

Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer

Ciamporcero, E., Daga, M., Pizzimenti, S., Roetto, A., Dianzani, C., Compagnone, A., Palmieri, A., Ullio, C., Cangemi, L., Pili, R. & Barrera, G., Feb 1 2018, In : Free Radical Biology and Medicine. 115, p. 447-457 11 p.

Research output: Contribution to journalArticle

Crosstalk
Urinary Bladder Neoplasms
Antioxidants
Cells
Transcription Factors
3 Citations (Scopus)

Dietary protein restriction reprograms tumor-associated macrophages and enhances immunotherapy

Orillion, A., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R., Affronti, H., Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., Elzey, B. D., Ratliff, T. L., Nelson, D. E., Smiraglia, D., Abrams, S. I. & Pili, R., Dec 15 2018, In : Clinical Cancer Research. 24, 24, p. 6383-6395 13 p.

Research output: Contribution to journalArticle

Dietary Proteins
Immunotherapy
Macrophages
Neoplasms
Amino Acids

Low-protein diet in cancer: Ready for prime time?

Pili, R. & Fontana, L., Jul 1 2018, In : Nature Reviews Endocrinology. 14, 7, p. 384-386 3 p.

Research output: Contribution to journalArticle

Protein-Restricted Diet
Diet
Diet Therapy
Neoplasms
Immune System
4 Citations (Scopus)

Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

Paller, C. J., Zhou, X. C., Heath, E. I., Taplin, M. E., Mayer, T., Stein, M. N., Bubley, G. J., Pili, R., Hudson, T., Kakarla, R., Abbas, M. M., Anders, N. M., Dowling, D., King, S., Bruns, A. B., Wagner, W. D., Drake, C. G., Antonarakis, E. S., Eisenberger, M. A., Denmeade, S. R. & 3 others, Rudek, M. A., Rosner, G. L. & Carducci, M. A., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 306-315 10 p.

Research output: Contribution to journalArticle

Controlled Clinical Trials
Vitis
Prostatic Neoplasms
Placebos
Skin
11 Citations (Scopus)

Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial

Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A., Widmark, A., Sternberg, C. N., Pili, R., Tuvesson, H., Nordle, Ö., Carducci, M. A. & Morris, M. J., Jul 1 2018, In : JAMA oncology. 4, 7, p. 944-951 8 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Randomized Controlled Trials
Biomarkers
Bone and Bones
3 Citations (Scopus)

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Monk, P., Liu, G., Stadler, W. M., Geyer, S., Huang, Y., Wright, J., Villalona-Calero, M., Wade, J., Szmulewitz, R., Gupta, S., Mortazavi, A., Dreicer, R., Pili, R., Dawson, N., George, S. & Garcia, J. A., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Disease-Free Survival
Proto-Oncogene Proteins c-met
1 Citation (Scopus)

Phase I trials of anti-ENPP3 antibody–drug conjugates in advanced refractory renal cell carcinomas

Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., Reyno, L., Wiseman, A., Trave, F., Anand, B., Morrison, K., Doñate, F. & Kollmannsberger, C. K., Sep 15 2018, In : Clinical Cancer Research. 24, 18, p. 4399-4406 8 p.

Research output: Contribution to journalArticle

Pyrophosphatases
Phosphoric Diester Hydrolases
Renal Cell Carcinoma
Hybridomas
Cricetulus

Tasquinimod targets suppressive myeloid cells in the tumor microenvironment

Shen, L. & Pili, R., May 3 2018, (Accepted/In press) In : OncoImmunology.

Research output: Contribution to journalArticle

Tumor Microenvironment
Myeloid Cells
Immunosuppressive Agents
Macrophages
Population
1 Citation (Scopus)

Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma

Adelaiye-Ogala, R., Damayanti, N. P., Orillion, A. R., Arisa, S., Chintala, S., Titus, M. A., Kao, C. & Pili, R., Jun 1 2018, In : Cancer Research. 78, 11, p. 2886-2896 11 p.

Research output: Contribution to journalArticle

Androgen Receptors
Renal Cell Carcinoma
Phosphorylation
Therapeutics
Receptor Protein-Tyrosine Kinases
4 Citations (Scopus)

Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma

Damayanti, N. P., Budka, J. A., Khella, H. W. Z., Ferris, M. W., Ku, S. Y., Kauffman, E., Wood, A. C., Ahmed, K., Chintala, V. N., Adelaiye-Ogala, R., Elbanna, M., Orillion, A., Chintala, S., Kao, C., Marston Linehan, W., Yousef, G. M., Hollenhorst, P. & Pili, R., Dec 1 2018, In : Clinical Cancer Research. 24, 23, p. 5977-5989 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Renal Cell Carcinoma
Therapeutics
S 6
High-Throughput Nucleotide Sequencing
2017

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Pili, R., Jegede, O., Carducci, M. A., Manola, J., Groteluschen, D. L., Appleman, L. L., Liu, G., Shanks, J. C., Dakhil, S. R., Dutcher, J. & DiPaola, R. S., Jan 5 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease Progression
Vascular Endothelial Growth Factor Receptor
aflibercept
Proteinuria
21 Citations (Scopus)

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

Pili, R., Liu, G., Chintala, S., Verheul, H., Rehman, S., Attwood, K., Lodge, M. A., Wahl, R., Martin, J. I., Miles, K. M., Paesante, S., Adelaiye, R., Godoy, A., King, S., Zwiebel, J. & Carducci, M. A., Feb 21 2017, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Clinical Trials, Phase I
Histone Deacetylase Inhibitors
Renal Cell Carcinoma
Disease-Free Survival
3 Citations (Scopus)

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., Rak, M., Attwood, K., Johnson, C., Morrison, C., Pili, R., Chatta, G., Guru, K., Gueron, G., McNally, L., Wang, J. & Woloszynska-Read, A., Dec 1 2017, In : Cell Death and Disease. 8, 12, 3217.

Research output: Contribution to journalArticle

decitabine
Urinary Bladder Neoplasms
Interleukin-6
Muscles
DNA
1 Citation (Scopus)

Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model

Affronti, H. C., Long, M. D., Rosario, S. R., Gillard, B. M., Karasik, E., Boerlin, C. S., Pellerite, A. J., Foster, B. A., Attwood, K., Pili, R., Wilton, J. H., Campbell, M. J. & Smiraglia, D. J., Jan 1 2017, In : Oncotarget. 8, 61, p. 103758-103774 17 p.

Research output: Contribution to journalArticle

Folic Acid
Prostatic Neoplasms
Recurrence
Androgens
Heterografts
39 Citations (Scopus)

Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma

Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., Gabrilovich, D. & Pili, R., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 5187-5201 15 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Tumor Microenvironment
Lung
Immunosuppressive Agents
Neoplasms
9 Citations (Scopus)

EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming

Adelaiye-Ogala, R., Budka, J., Damayanti, N. P., Arrington, J., Ferris, M., Hsu, C. C., Chintala, S., Orillion, A., Miles, K. M., Shen, L., Elbanna, M., Ciamporcero, E., Arisa, S., Pettazzoni, P., Draetta, G. F., Seshadri, M., Hancock, B., Radovich, M., Kota, J., Buck, M. & 9 others, Keilhack, H., McCarthy, B. P., Persohn, S. A., Territo, P., Zang, Y., Irudayaraj, J., Tao, W. A., Hollenhorst, P. & Pili, R., Dec 1 2017, In : Cancer Research. 77, 23, p. 6651-6666 16 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Receptor Protein-Tyrosine Kinases
Transferases
Drug Resistance
Heterografts
17 Citations (Scopus)

Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: A multicenter, single-arm, phase I/II trial (NCI-CTEP#7870)

Pili, R., Quinn, D. I., Hammers, H. J., Monk, P., George, S., Dorff, T. B., Olencki, T., Shen, L., Orillion, A., Lamonica, D., Fragomeni, R. S., Szabo, Z., Hutson, A., Groman, A., Perkins, S., Piekarz, R. & Carducci, M. A., Dec 1 2017, In : Clinical Cancer Research. 23, 23, p. 7199-7208 10 p.

Research output: Contribution to journalArticle

Immunomodulation
Renal Cell Carcinoma
Interleukin-2
Confidence Intervals
Disease-Free Survival
3 Citations (Scopus)

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Wentink, M. Q., Verheul, H. M. W., Pal, S. K., George, S., Voortman, J., Danchaivijitr, P., Adelaiye, R., Poslinski, D., Groman, A., Hutson, A. & Pili, R., 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Dalteparin
Renal Cell Carcinoma
Factor Xa
Therapeutics
Low Molecular Weight Heparin
3 Citations (Scopus)
Genetic Heterogeneity
Fluorescence In Situ Hybridization
Renal Cell Carcinoma
Neoplasms
Chromosome Deletion
2 Citations (Scopus)

Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells

Damayanti, N. P., Buno, K., Cui, Y., Voytik-Harbin, S. L., Pili, R., Freeman, J. & Irudayaraj, J. M. K., Aug 25 2017, In : ACS Sensors. 2, 8, p. 1225-1230 6 p.

Research output: Contribution to journalArticle

phosphorylation
Phosphorylation
Phosphotransferases
Cells
sensors
6 Citations (Scopus)

Selenomethionine and methyl selenocysteine: Multiple-dose pharmacokinetics in selenium-replete men

Marshall, J. R., Burk, R. F., Ondracek, R. P., Hill, K. E., Perloff, M., Davis, W., Pili, R., George, S. & Bergan, R., 2017, In : Oncotarget. 8, 16, p. 26312-26322 11 p.

Research output: Contribution to journalArticle

Selenomethionine
Selenium
Pharmacokinetics
Neoplasms
Yeasts
7 Citations (Scopus)

Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device

Huang, W., Chang, C. L., Brault, N. D., Gur, O., Wang, Z., Jalal, S., Low, P. S., Ratliff, T. L., Pili, R. & Savran, C. A., 2017, In : Lab on a Chip - Miniaturisation for Chemistry and Biology. 17, 3, p. 415-428 14 p.

Research output: Contribution to journalArticle

Biomarkers
Antigens
Prostatic Neoplasms
Cells
Proteins
2016
254 Citations (Scopus)

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., Wilding, G., Cella, D., Wagner, L., Matin, S., Kuzel, T. M., Sexton, W. J., Wong, Y. N., Choueiri, T. K., Pili, R., Puzanov, I. & 5 others, Kohli, M., Stadler, W., Carducci, M., Coomes, R. & Dipaola, R. S., May 14 2016, In : The Lancet. 387, 10032, p. 2008-2016 9 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Placebos
sorafenib
sunitinib
Disease-Free Survival
1 Citation (Scopus)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Pili, R., Van Der Vliet, H. J., De Gruijl, T. D. & Verheul, H. M. W., Oct 11 2016, In : British Journal of Cancer. 115, 8, p. 940-948 9 p.

Research output: Contribution to journalArticle

Biological Assay
Vascular Endothelial Growth Factor A
Anti-Idiotypic Antibodies
Neoplasms
Therapeutics
40 Citations (Scopus)

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F., Pili, R., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., Mamlouk, K., Ferrante, K. J. & Taplin, M. E., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1356-1363 8 p.

Research output: Contribution to journalArticle

Castration
Androgen Receptors
Prostatic Neoplasms
Safety
Therapeutics
27 Citations (Scopus)

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L., Cheng, L., Nassiri, M., Davidson, D., Rushing, D. A., Loehrer, P., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T., Helft, P., Shahda, S. & 2 others, O'Neil, B. H. & Schneider, B., 2016, In : Oncotarget. 7, 35, p. 56491-56500 10 p.

Research output: Contribution to journalArticle

Precision Medicine
Disease-Free Survival
Neoplasms
Therapeutics
Standard of Care
13 Citations (Scopus)

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation

Wang, J., Papanicolau-Sengos, A., Chintala, S., Wei, L., Liu, B., Hu, Q., Miles, K. M., Conroy, J. M., Glenn, S. T., Costantini, M., Magi-Galluzzi, C., Signoretti, S., Choueiri, T., Gallucci, M., Sentinelli, S., Fazio, V. M., Poeta, M. L., Liu, S., Morrison, C. & Pili, R., May 24 2016, In : Oncotarget. 7, 21, p. 29901-29915 15 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Up-Regulation
Genes
Cisplatin
Single Nucleotide Polymorphism
3 Citations (Scopus)

Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer

Ellis, L., Ku, S. Y., Li, Q., Azabdaftari, G., Seliski, J., Olson, B., Netherby, C. S., Tang, D. G., Abrams, S. I., Goodrich, D. W. & Pili, R., Sep 15 2016, In : Prostate. 76, 13, p. 1192-1202 11 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Cell Line
Tumor Microenvironment
Prostate
Transgenic Mice
15 Citations (Scopus)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts

Wei, L., Chintala, S., Ciamporcero, E., Ramakrishnan, S., Elbanna, M., Wang, J., Hu, Q., Glenn, S. T., Murakami, M., Liu, L., Gomez, E. C., Sun, Y., Conroy, J., Miles, K. M., Malathi, K., Ramaiah, S., Anbarasu, A., Woloszynska-Read, A., Johnson, C. S., Conroy, J. & 3 others, Liu, S., Morrison, C. D. & Pili, R., 2016, In : Oncotarget. 7, 47, p. 76374-76389 16 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Heterografts
Urinary Bladder Neoplasms
Cisplatin
Mutation
10 Citations (Scopus)

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

Ramakrishnan, S., Ku, S. Y., Ciamporcero, E., Miles, K. M., Attwood, K., Chintala, S., Shen, L., Ellis, L., Sotomayor, P., Swetzig, W., Huang, R., Conroy, D., Orillion, A., Das, G. & Pili, R., 2016, In : BMC Cancer. 16, 1, 617.

Research output: Contribution to journalArticle

Histone Deacetylases
Renal Cell Carcinoma
Cell Movement
Protein Isoforms
Cell Line
25 Citations (Scopus)

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

Pokuri, V. K., Syed, J. R., Yang, Z., Field, E. P., Cyriac, S., Pili, R., Levine, E. G., Azabdaftari, G., Trump, D. L., Guru, K. & George, S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. e59-e65

Research output: Contribution to journalArticle

Urinary Bladder
Carcinoma
Drug Therapy
Muscles
Cystectomy
25 Citations (Scopus)

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

Deng, X., Shao, G., Zhang, H. T., Li, C., Zhang, D., Cheng, L., Elzey, B. D., Pili, R., Ratliff, T. L., Huang, J. & Hu, C. D., Aug 22 2016, (Accepted/In press) In : Oncogene.

Research output: Contribution to journalArticle

Protein-Arginine N-Methyltransferases
Androgen Receptors
Epigenomics
Prostatic Neoplasms
Growth
41 Citations (Scopus)

Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer

Sternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., Khvorostenko, D., Lyulko, O., Brize, A., Vogelzang, N., Delva, R., Harza, M., Thanos, A., James, N., Werbrouck, P., Bögemann, M., Hutson, T., Milecki, P., Chowdhury, S., Gallardo, E. & 6 others, Schwartsmann, G., Pouget, J. C., Baton, F., Nederman, T., Tuvesson, H. & Carducci, M., Aug 1 2016, In : Journal of Clinical Oncology. 34, 22, p. 2636-2643 8 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Survival
Disease-Free Survival
3 Citations (Scopus)

Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab

Adra, N., Cheng, L. & Pili, R., Dec 17 2016, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Kidney Neoplasms
Renal Cell Carcinoma
Immunotherapy
Therapeutics
nivolumab
42 Citations (Scopus)

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

Ciamporcero, E., Shen, H., Ramakrishnan, S., Yu Ku, S., Chintala, S., Shen, L., Adelaiye, R., Miles, K. M., Ullio, C., Pizzimenti, S., Daga, M., Azabdaftari, G., Attwood, K., Johnson, C., Zhang, J., Barrera, G. & Pili, R., Mar 24 2016, In : Oncogene. 35, 12, p. 1541-1553 13 p.

Research output: Contribution to journalArticle

DNA Damage
Carcinoma
Proteins
Cisplatin
Drug Therapy
2015
51 Citations (Scopus)

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular Cancer Therapeutics. 14, 1, p. 101-110 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Neoplasms
Therapeutics
Growth
3 Citations (Scopus)

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer

Kalmuk, J., Folaron, M., Buchinger, J., Pili, R. & Seshadri, M., 2015, In : Oncotarget. 6, 27, p. 24376-24392 17 p.

Research output: Contribution to journalArticle

Multimodal Imaging
Blood Vessels
Prostatic Neoplasms
Neoplasms
Castration
50 Citations (Scopus)

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Weiss, A., Ding, X., van Beijnum, J. R., Wong, I., Wong, T. J., Berndsen, R. H., Dormond, O., Dallinga, M., Shen, L., Schlingemann, R. O., Pili, R., Ho, C. M., Dyson, P. J., van den Bergh, H., Griffioen, A. W. & Nowak-Sliwinska, P., Jul 20 2015, In : Angiogenesis. 18, 3, p. 233-244 12 p.

Research output: Contribution to journalArticle

Drug Combinations
Endothelial cells
Endothelial Cells
Pharmaceutical Preparations
Neoplasms
18 Citations (Scopus)

Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model

Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R. & Fontana, L., 2015, In : Oncotarget. 6, 31, p. 31233-31240 8 p.

Research output: Contribution to journalArticle

Dietary Proteins
Heterografts
Fasting
Neoplasms
Proteins
35 Citations (Scopus)

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

Adelaiye, R., Ciamporcero, E., Miles, K. M., Sotomayor, P., Bard, J., Tsompana, M., Conroy, D., Shen, L., Ramakrishnan, S., Ku, S. Y., Orillion, A., Prey, J., Fetterly, G., Buck, M., Chintala, S., Bjarnasone, G. A. & Pili, R., Feb 1 2015, In : Molecular Cancer Therapeutics. 14, 2, p. 513-522 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Epigenomics
sunitinib
Neoplasms
Histone Code
41 Citations (Scopus)

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models

Shen, L., Sundstedt, A., Ciesielski, M., Miles, K. M., Celander, M., Adelaiye, R., Orillion, A., Ciamporcero, E., Ramakrishnan, S., Ellis, L., Fenstermaker, R., Abrams, S. I., Eriksson, H., Leanderson, T., Olsson, A. & Pili, R., Feb 1 2015, In : Cancer immunology research. 3, 2, p. 136-148 13 p.

Research output: Contribution to journalArticle

Myeloid Cells
Immunotherapy
Neoplasms
Immunosuppressive Agents
Prostatic Neoplasms
37 Citations (Scopus)

Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer

Kirk, J. S., Schaarschuch, K., Dalimov, Z., Lasorsa, E., Ku, S. Y., Ramakrishnan, S., Hu, Q., Azabdaftari, G., Wang, J., Pili, R. & Ellis, L., 2015, In : Oncotarget. 6, 5, p. 3136-3146 11 p.

Research output: Contribution to journalArticle

Epigenomics
Prostatic Neoplasms
Etoposide
Therapeutics
Neoplasms
2014
16 Citations (Scopus)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journalArticle

Microvessels
Heterografts
Colonic Neoplasms
Neoplasms
sunitinib
5 Citations (Scopus)

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journalArticle

30 Citations (Scopus)

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

Renal Cell Carcinoma
Disease-Free Survival
Smoking
Survival
Hypertension
10 Citations (Scopus)

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journalArticle

DNA Methylation
Renal Cell Carcinoma
Formaldehyde
Chromatin
Neoplasms
4 Citations (Scopus)

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journalArticle

Maximum Tolerated Dose
Protein-Tyrosine Kinases
Neoplasms
Neutropenia
Vascular Endothelial Growth Factor A